Status:
COMPLETED
Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Reflux
Eligibility:
MALE
18-45 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.
Detailed Description
A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers...
Eligibility Criteria
Inclusion
- Provision of signed informed consent
- Healthy male subjects
- Age 18-45 years, inclusive
Exclusion
- Clinically significant illness within the 2 weeks prior to the first dose of study drug
- History of clinically significant cardiovascular, respiratory, renal, hepatic, neurological, mental or gastrointestinal disease
- Need for concomitant medications during the study
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01154634
Start Date
May 1 2010
End Date
September 1 2010
Last Update
August 30 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Leuven, Belgium
2
Research Site
Amsterdam, Netherlands